|
SEPT7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.23490000237103E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.68360999999173E-05 |
| Normal-vs-Stage2 |
1.374480E-04 |
| Normal-vs-Stage3 |
2.24250000013804E-07 |
| Normal-vs-Stage4 |
4.86679999966988E-07 |
| Stage1-vs-Stage2 |
5.463800E-01 |
| Stage1-vs-Stage3 |
1.272200E-01 |
| Stage1-vs-Stage4 |
7.847700E-02 |
| Stage2-vs-Stage3 |
6.466000E-01 |
| Stage2-vs-Stage4 |
3.954000E-01 |
| Stage3-vs-Stage4 |
6.347000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.32309999973424E-07 |
| Normal-vs-AfricanAmerican |
3.040900E-03 |
| Normal-vs-Asian |
7.398900E-03 |
| Caucasian-vs-AfricanAmerican |
6.918400E-01 |
| Caucasian-vs-Asian |
2.474000E-01 |
| AfricanAmerican-vs-Asian |
6.903400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.8440000000286E-06 |
| Normal-vs-Female |
1.39800000020784E-07 |
| Male-vs-Female |
5.873800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.87900000000663E-05 |
| Normal-vs-Age(41-60Yrs) |
1.52519999963019E-07 |
| Normal-vs-Age(61-80Yrs) |
2.17710000027793E-07 |
| Normal-vs-Age(81-100Yrs) |
3.886000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.115970E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.667600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.838200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.757400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.133800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.107200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.254200E-01 |
| Classical-VS-Follicular |
2.135400E-03 |
| Classical-VS-Other |
1.412040E-01 |
| Classical-VS-Normal |
1.161980E-04 |
| Tall-VS-Follicular |
3.052200E-01 |
| Tall-VS-Other |
3.728200E-01 |
| Tall-VS-Normal |
1.243310E-03 |
| Follicular-VS-Other |
6.922200E-01 |
| Follicular-VS-Normal |
1.21240000039435E-07 |
| Other-VS-Normal |
3.100100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.9224999914822E-09 |
| Normal-vs-N1 |
2.27389999999383E-05 |
| N0-vs-N1 |
9.329400E-01 |
|
|
